NHS Greater Glasgow & Clyde Area Drug and Therapeutics Committee
Greater Glasgow and Clyde Medicines

GGC Formulary
- 1 Gastro-intestinal system
- 2 Cardiovascular system
- 3 Respiratory system
- 4 Central nervous system
- 5 Infections
- 6 Endocrine system
- 7 Obstetrics, gynaecology and urinary-tract disorders
- 8 Malignant disease and immunosuppression
- 9 Nutrition and blood
- 10 Musculoskeletal and joint diseases
- 11 Eye
- 12 Ear, nose and oropharynx
- 13 Skin
- 14 Immunological products and vaccines
  - 14.4 Vaccines and antisera
  - 14.5 Immunoglobulins
- 15 Anaesthesia
  - 15.1 General anaesthesia
  - 15.2 Local anaesthesia
- 16 Treatment of poisoning
  - 16.1 Removal and elimination
  - 16.2 Specific antidotes
- 17 Test Chapter
  - 17.1 Test Layout: Hypertension
Latest Formulary Decisions
Medicines Update Bulletins
Clinical Guidelines
Adult Therapeutics Handbook
Medicines Policies
Other Formularies
Non-Formulary and IPTR
Patient Information
Prescribing Resources
Shared Care Agreements
Contact Us

Go Home

Subscribe to Medicines Update via

Email Subscription

Latest Medicines Update Posts

Archives

Tags

Medicines Update

Sacubitril / valsartan

Heart MCN Key Message

All new initiations of sacubitril/valsartan must be discussed on an individual patient basis with a consultant with special interest in heart failure. For safety reasons, every patient commenced on sacubitril/valsartan should be under the care of the Heart Failure Liaison Nurses through-out the initiation and up-titration phase.

NHSGGC guidelines on Sacubitril/Valsartan are available on Staffnet

Published 25/4/17